spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  daytime sleepiness 

 HSMN NewsFeed - 8 Jun 2023
Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 25 Jun 2021
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Oct 2020
Citrine Medicine Advances Efforts to Create the Very First Rare Disease Ecosystem in China Through Strategic Partnership with Bioprojet to License Exclusive Rights for the Use of Orphan Narcolepsy Therapy Wakix(R) (pitolisant)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Oct 2020
Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX(R) (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2020
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 Apr 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Aug 2019
Vanda Pharmaceuticals FDA Update for HETLIOZ(R) in the Treatment of Jet Lag Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Aug 2019
Harmony Biosciences Announces FDA Approval of WAKIX(R) (Pitolisant), a First-in-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Jan 2015
Mundipharma receives positive European Commission decision on Targin(R) (oxycodone/naloxone) for the treatment of Restless Legs Syndrome1
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Jan 2014
Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Aug 2013
Respicardia Announces Enrollment Of First Patients In Pivotal Trial Of The remede(R) System For The Treatment Of Central Sleep Apnea
Devices
 HSMN NewsFeed - 17 May 2013
New Study Shows Effect of Neupro(R) (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2012
Jay Millerhagen Joins Respicardia(R) as Vice President of Clinical Affairs and Market Development
Devices Personnel
 HSMN NewsFeed - 18 May 2012
ApniCure Receives FDA 510(k) Clearance to Market Winx(TM) Sleep Therapy System for Treatment of Obstructive Sleep Apnea
Devices FDA
 HSMN NewsFeed - 30 Nov 2010
Inspire Medical Systems Announces FDA approval for Pivotal Clinical Trial
Devices Neurology FDA
 HSMN NewsFeed - 2 Jun 2010
Apnex Medical, Inc. Names Chas McKhann President, Chief Executive Officer
Devices Neurology Personnel
 HSMN NewsFeed - 3 Dec 2009
Apnex Medical, Inc. Raises Additional $14 Million
Devices Venture Capital
 HSMN NewsFeed - 3 Dec 2009
Nasal-Aire(R) II Petite Receives FDA 510(k) Clearance for Pediatric Use
Devices FDA
 HSMN NewsFeed - 13 May 2009
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Sep 2008
Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
SPO Medical Launching Enhanced PulseOx 7500(TM) Oximetry System
Devices Monitoring
 HSMN NewsFeed - 10 Jun 2008
New Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2008
New Data Confirm Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Sleep Disturbance for People With Restless Legs Syndrome (RLS)
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 13 Jul 2007
Jazz Pharmaceuticals Announces Settlement of Government Investigation
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2007
Aspire Medical Announces First Implant in US and Start of Clinical Trial to Treat Sleep Apnea
Devices
 HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2007
Aspire Medical Appoints Roseanne Varner as President and CEO
Devices Personnel
 HSMN NewsFeed - 2 Apr 2007
Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jan 2007
Valeant Pharmaceuticals Signs Licensing Agreement for Canadian Rights to Xyrem(R) (Sodium Oxybate) from Jazz Pharmaceuticals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Jan 2007
Hypnion Announces Positive and Robust Phase II Results for Novel Sleep Drug - HY10275
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
Six New Studies Document Efficacy and Sustained Benefit of Restore Medical's Pillar(R) Procedure
Devices
 HSMN NewsFeed - 3 Oct 2006
UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem(R) License Agreement to Include Fibromyalgia Syndrome
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Sep 2006
Jazz Pharmaceuticals Announces Phase III Clinical Trial to Study the Safety and Efficacy of Xyrem(R) (Sodium Oxybate) in Patients With Fibromyalgia Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 6 Mar 2006
Xyrem(R) (Sodium Oxybate) Now Available for the Treatment of Excessive Daytime Sleepiness (EDS) in Patients With Narcolepsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2006
Study Finds That Xyrem(R) (Sodium Oxybate) Relieves Pain in Patients With Fibromyalgia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
daytime sleepiness
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.